1885.30
-4.53%
Emkay
MHL’s Q3FY25 EBITDA missed street/our estimates by 9%/4%, with revenue growing 11% YoY driven by B2C revenue improving 15% YoY.
Metropolis Healthcare Ltd. average weekly volume is high.
More from Metropolis Health…
All earning calls
Investor presentations from Metropolis Health…
All investor presentations